Skip to main content
. Author manuscript; available in PMC: 2017 Jan 20.
Published in final edited form as: Anticancer Res. 2014 Jul;34(7):3357–3363.

Figure 4.

Figure 4

Effect of dietary Lipitor and Celebrex on the growth of orthotopic VCaP prostate cancer tumors in SCID mice and expression of B cell lymphoma 2 (Bcl2) in the tumors. SCID mice were injected orthotopically with VCaP-luc cells (1×106 cells/mouse). After four weeks, mice with established VCaP tumors were fed AIN76A diet (9 mice) or AIN76A diet containing 0.02% Lipitor and 0.05% Celebrex (10 mice) for 28 days. Tumor size in each mouse was determined once a week using the IVIS system. Representative images are shown. A and B: A mouse of the control group before and after treatment; C and D: a mouse of the group treated with Lipitor and Celebrex before and after treatment. E: Percentage of initial tumor size in the control group and the group treated with Lipitor (LIP) and Celebrex (CEL) . Each value represents the mean± S.E. Differences in the tumor size between the control group and the treatment group was analyzed by Student t-test. *p<0.001. F: A representative micrograph of immunohistochemistry in a tumor from the control group shows brown staining of Bcl2. G: A representative micrograph of immunohistochemistry in a tumor from the Lipitor and Celebrex-treated group shows reduced brown staining of Bcl2.